ALX Oncology Holdings Inc. has released its financial results for the third quarter ended September 30, 2026. This update is significant as it provides insights into the company's operational performance and financial health during a critical period.
ALX Oncology Holdings Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol ALXO. Recent filings include a 10-Q and another 8-K, both filed on November 16, 2026, indicating a busy reporting period for the company.
The latest filing reveals that on November 16, 2026, ALX Oncology issued a press release detailing its financial results for the third quarter. The press release is included as Exhibit 99.1 in the filing. However, specific financial metrics and performance details were not disclosed in the filing itself.
This announcement may affect various stakeholders, including investors, analysts, and competitors within the pharmaceutical preparations sector. The financial results could shape investor perceptions and influence stock performance moving forward.
As for future developments, the filing does not specify what actions will follow this announcement. Investors and industry observers will likely keep an eye on ALX Oncology's upcoming communications for additional insights.
Company Overview
ALX Oncology Holdings Inc. is incorporated in Delaware and operates primarily out of South San Francisco, California. The company is classified under the SIC code 2834, which pertains to pharmaceutical preparations. As of the date of the filing, ALX Oncology's Employer Identification Number (EIN) is 85-0642577, and it is registered with the SEC under file number 001-39386.
Recent Developments
The press release mentioned in the filing, which is included as Exhibit 99.1, may provide further insights into the company's strategic direction and operational initiatives. However, specific financial metrics, such as revenue, net income, or earnings per share, were not disclosed in the 8-K filing itself.
Contact Information
For further inquiries, ALX Oncology can be reached at their business address: 323 Allerton Avenue, South San Francisco, CA 94080. The company's business phone number is 650-466-7125.
Note: The filing does not include specific financial results or metrics from the third quarter, which may be crucial for stakeholders assessing the company's performance.
Read Next
Vanjia Corp reports Q3 2026 financial results
Sparxx Corp reports Q3 2026 results, shows growth trends
iWallet Corp Reports Q3 Results, Highlights Financial Strategy
HarbourVest Private Equity Secondaries Fund Reports Q2 Results
INVO Fertility Reports 28% Revenue Growth in Q3 Results
KEEMO Fashion Group Reports No Revenue in Latest 10-Q Filing








